secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACTUATE THERAPEUTICS, INC. (ACTU)
CIK:        0001652935
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001683168-25-004258
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Actuate Therapeutics presents Phase 2 elraglusib data showing overall survival benefit in pancreatic cancer
--------------------------------------------------------------------------------

- Phase 2 (Actuate-1801 Part 3B) data of elraglusib with gemcitabine/nab-paclitaxel showed overall survival benefit in first-line metastatic pancreatic cancer.
- KOL event featured four GI oncology experts who discussed elraglusib's mechanism targeting EMT, NF-kB, and immune activation.
- Dr. Colin Weekes stated elraglusib is the first drug in years to improve outcomes on standard chemotherapy backbones.
- Drug was well-tolerated; neutropenia occurred but no febrile neutropenia; transient vision changes resolved within 24 hours.
- Study PI Dr. Deva Mahalingam highlighted unique GSK-3 beta inhibition and survival curve separation in a challenging patient population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652935/000168316825004258/0001683168-25-004258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652935/000168316825004258/actuate_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-004258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer